Company Filing History:
Years Active: 1997
Title: Jaakko Lappalainen: Innovator in Serotonin Receptor Research
Introduction: Jaakko Lappalainen, an esteemed inventor based in Bethesda, MD, has made significant contributions to the field of genetic research. With a focus on the serotonin 5-HT2C receptor, Lappalainen’s work has advanced the understanding of genetic variations and their implications in human health.
Latest Patents: Lappalainen holds a patent titled "Allelic variation of the serotonin 5HT.sub.2c receptor". This invention describes the identification of a non-conservative amino acid substitution in the 5-HT2C receptor gene. Utilizing single strand conformational polymorphism (SSCP) analysis, he discovered this variant and genetically mapped the gene to the long arm of the X chromosome. Lappalainen went further to develop a PCR-RFLP based method for rapid genotyping in populations and families, which addresses limitations found in conventional RFLP methods.
Career Highlights: Jaakko Lappalainen works for the Department of Health, United States of America, where he has been at the forefront of research on serotonin receptors. His work is not only pivotal in pharmacogenomics but also aids in understanding various psychological conditions linked to serotonin pathways.
Collaborations: Throughout his career, Lappalainen has collaborated with notable researchers such as Markku I Linnoila and David Goldman. These collaborations have fueled advancements in the understanding of genetics and its applications in medicine.
Conclusion: Jaakko Lappalainen's contributions to genetic research, particularly with the serotonin 5-HT2C receptor, demonstrate the valuable impact that dedicated inventors have on science and health. With his ongoing efforts and collaborative work, he continues to pave the way for future innovations in this critical field.